Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob
Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger.
The medical device manufacturer in January agreed to acquire Axonics for about $3.7 billion in cash, resulting in Axonics becoming a wholly-owned subsidiary of Boston Scientific.
The additional request for information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both sides have substantially complied with the request, Boston Scientific said in a securities filing.
The merger is now expected to be completed in the second half of 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks